ライフサイエンスコーパス: immunoediting

1 etastatic progression, suggesting neoantigen immunoediting.

2 pport of the likelihood of NK-mediated tumor immunoediting.

3 related to immune equilibrium during cancer immunoediting.

4 whether innate immunity alone is capable of immunoediting.

5 ich act as important effectors during cancer immunoediting.

6 n process represents one mechanism of cancer immunoediting.

7 genesis to investigate the process of cancer immunoediting.

8 ctions of immunity are referred to as cancer immunoediting.

9 orally distinct from IFN-gamma during cancer immunoediting.

10 pe mechanisms of tumor cells selected during immunoediting.

11 anisms, including induction of tolerance and immunoediting.

12 sms leading to cancer immunosurveillance and immunoediting.

13 ening of this concept into one termed cancer immunoediting.

14 omponent of a more general process of cancer immunoediting.

15 issue identification, resulting from epitope immunoediting.

16 at innate immune cells could manifest cancer immunoediting activity in the absence of adaptive immuni

17 ific antigens by lymphocytes is critical for immunoediting against sarcomas.

18 echanisms by which CD1e contributes to lipid immunoediting and CD1-restricted presentation to T cells

19 historical and experimental basis of cancer immunoediting and discuss its dual roles in promoting ho

20 s a lipid transfer protein influencing lipid immunoediting and membrane transfer of PIM lipids.

21 Cancer immunoediting describes the process whereby highly immun

22 enesis or in the elimination phase of cancer immunoediting, did not play critical roles in maintainin

23 sults support that MHC-I genotype-restricted immunoediting during tumor formation shapes the landscap

24 on and evolution into the three Es of cancer immunoediting--elimination, equilibrium, and escape.

25 cient mice recapitulated the three phases of immunoediting: elimination, equilibrium, and escape.

26 Cancer immunoediting explains the dual role by which the immune

27 idual DCIS, suggesting an active process of "immunoediting" for HER-2/neu-expressing tumor cells foll

28 eshift mutations, showed genetic evidence of immunoediting, had higher densities of Th1, effector-mem

29 Cancer immunoediting has been postulated to contribute to the e

30 ar, the importance of CD8+ T cells in cancer immunoediting has been shown, and more broadly in those

31 The principles of cancer immunoediting have set the foundations for understanding

32 provide experimental support for the cancer immunoediting hypothesis, but we also show that aggressi

33 so discuss the temporal occurrence of cancer immunoediting in metastases and whether it differs from

34 Immunoediting in NKC(KD) mice was restricted to MHC-I mo

35 In this study, we evaluated immunoediting in the neu-transgenic mouse model of breas

36 ng in metastases and whether it differs from immunoediting in the primary tumor of origin.

37 imination or the equilibrium phase of cancer immunoediting in the small intestine in this model.

38 r progression, independently of any need for immunoediting in the tumor microenvironment.

39 r genetic findings thus provide evidence for immunoediting in tumors and uncover mechanisms of tumor-

40 illance constitutes the first step of cancer immunoediting in which developing malignant lesions are

41 This occurs through a novel mechanism of immunoediting, in which modulation of the quaternary str

42 veillance hypothesis into one termed "cancer immunoediting." In this review, we summarize the history

43 Cancer immunoediting is a process by which immune cells, partic

44 Cancer immunoediting is a process consisting of three phases: e

45 A central tenet of cancer immunoediting is that T-cell recognition of tumour antig

46 Cancer immunoediting is the process whereby immune cells protec

47 Cancer immunoediting is the process whereby the immune system s

48 'Cancer immunoediting' is a process wherein the immune system pr

49 to control and shape cancer, that is, cancer immunoediting, is the result of three processes that fun

50 mmune function that accumulate during cancer immunoediting lead to a progressive escape from host imm

51 We also demonstrate that cancer immunoediting of d42m1 occurs via a T-cell-dependent imm

52 These results suggest that immunoediting of tumor results in cellular reprogramming

53 Immunoediting of tumor-associated antigens occurs in res

54 ild-type mice, suggesting an NKG2D-dependent immunoediting of tumors in this model.

55 ng the existence of each of the three cancer immunoediting phases.

56 erons are important components of the cancer immunoediting process and function in a way that does no

57 and human clinical data supporting a cancer immunoediting process that provide the fundamental basis

58 plex I was necessary and sufficient for this immunoediting process to occur.

59 ur understanding of each phase of the cancer immunoediting process, summarizes the discovery of new p

60 dress the role of IFN-gamma in mediating the immunoediting process.

61 , many questions about the process of cancer immunoediting remain unanswered, in part because of the

62 Immunoediting results in reshaping the immunogenicity of

63 During cancer immunoediting, the ability of the tumor to escape immune

64 During cancer immunoediting, the host immune system shapes tumour fate

65 Cancer immunoediting, the process by which the immune system co

66 Cancer immunoediting, the process by which the immune system co

67 Thus, during immunoediting, tumor cell populations evolve strategies

68 Although cancer immunoediting was first demonstrated using mouse models

69 he stresses of innate and adaptive immunity (immunoediting), which provoke epigenetic changes in the

70 unifying conceptual framework called "cancer immunoediting," which integrates the immune system's dua

71 munobiology of cancer immunosurveillance and immunoediting will hopefully stimulate development of mo